



Celldex Therapeutics, Inc.
Investor Relations Department
119 Fourth Avenue
Needham, MA 02494-2725
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CLDX ¹	
Last Trade:	2.77
Trade Time:	11:27 AM ET Jan 22, 2018
Change:	0.01 (0.181%)
Day Range	2.76 - 2.80
52-Week Range	2.20 - 3.94
Volume	421,137
Market Cap. (\$M)	376.012
Shares Out (M)	135.990

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 30, 2017 [Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors](#)
- Nov 17, 2017 [Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma](#)
- Nov 7, 2017 [Celldex Reports Third Quarter 2017 Results](#)
- Oct 3, 2017 [Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs](#)
- Sep 22, 2017 [Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

- Mar 14, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Definitive Proxy Statement](#)
- Nov 7, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 8, 2017 [Quarterly Report \(10-Q\)](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)